Asthma

AI enhances prediction, diagnosis, and treatment of allergic diseases including asthma, atopic dermatitis, and food allergies, offering personalized, efficient care.

New triple therapy BGF shows significant and clinically meaningful lung function improvement in patients with uncontrolled asthma, with full data readouts coming soon.

The month in review spotlights new data for COPD and bronchiectasis, as well as new research and conversations around smoking.

Overall, Asthma Control Test (ACT) measures improved by 37%.

Acute respiratory infection caused by RSV results in a nearly 3-fold increase in mortality, particularly in those with underlying respiratory conditions.

Our Q1 2025 recap for pulmonology spotlights 5 regulatory updates, 5 key trial announcements, and top expert perspectives in pulmonology care. Read now:

Participants with higher baseline eosinophil levels had the greatest responses and no participants experienced peaks of over 3000 eosinophils/µL.

This March 2025 month in review covers key pulmonology updates, including new findings on pulmonary function tests and expert insights from the AAAAI/WAO Joint Congress.

A new cross-sectional study found that the odds of having bronchodilator responsiveness declined by 8% per hour during the working day.

Our top 5 headlines featured an oral drug delivering 16% weight loss, notable blood pressure reductions from a hypertension treatment, and 3 key FDA decisions.

Hoyte discussed findings from a post hoc analysis of the phase 3 NAVIGATOR study.

Chambliss also discussed other research she is working on looking to understand effects on children with asthma.

A real-world study shows benralizumab significantly reduced severe asthma exacerbations in older adults, with a 43.5% decrease in annual rates.

Lipworth shared findings from 2 studies that he presented data from at the AAAAI/WAO Joint Congress.

Chambliss and colleagues found a 1% increase in asthma-related emergency department visits per unit of distance to semiconductor fabrication plants.

This February 2025 month in review covers key pulmonology updates, including FDA reviews for brensocatib and PRGN-2012, dupilumab’s COPD data, and wildfire air quality risks.

Findings were presented from the AROMA registry study in 3 abstracts at the AAAAI,WAO Joint Congress.

Subgroup analyses of the real-world REALITI-A study were presented at the 2025 AAAAI/WAO Joint Congress.

There was a 79% relative reduction in annualized asthma exacerbation rate in the 6 months after starting treatment compared with the prior 6 months.

Dupilumab improved R5–R20 and AX compared to placebo, possibly explaining improvements in disease control.

In this quiz, we test your knowledge of the latest guideline recommendations for aspirin therapy in AERD.

Three subgroup analyses of the phase 3 NAVIGATOR study are set to be presented at the AAAAI/WAO Joint Congress.

Targeted Genomics’ GHR test uses NGS to detect genetic variants in genomic DNA isolated from at-home collected saliva samples.

Despite being aware of its value in treating asthma, specialists were uncertain about integrating ITT into patient care.